vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Company Growth (employees)
vTv Therapeutics was founded in 1998 and is headquartered in High Point, US
vTv Therapeutics Office Locations
vTv Therapeutics has an office in High Point
High Point, US (HQ)
4170 Mendenhall Oaks Pkwy
vTv Therapeutics Data and Metrics
vTv Therapeutics Financial Metrics
vTv Therapeutics's revenue was reported to be $634 k in FY, 2016 which is a 22% increase from the previous period.
USD
Revenue (FY, 2016) | 634 k |
Revenue growth (FY, 2015 - FY, 2016), % | 22% |
Net income (FY, 2016) | (55.4 m) |
EBIT (FY, 2016) | (55 m) |
Market capitalization (28-Jun-2017) | 45.9 m |
Closing share price (28-Jun-2017) | 4.8 |
Cash (31-Dec-2016) | 51.5 m |
EV | 16.6 m |
vTv Therapeutics's current market capitalization is $45.9 m.
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 519 k | 634 k |
Revenue growth, % | 22% | |
R&D expense | 27.2 m | 45 m |
General and administrative expense | 9.1 m | 9.9 m |
Operating expense total | 38.7 m | 55.7 m |
EBIT | (38.1 m) | (55 m) |
EBIT margin, % | (7349%) | (8678%) |
Interest expense | (68 k) | (398 k) |
Interest income | 87 k | |
Net Income | (55.4 m) |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 88 m | 51.5 m |
Inventories | 1.1 m | 612 k |
Current Assets | 89.2 m | 52.1 m |
PP&E | 624 k | 444 k |
Total Assets | 91.5 m | 54.5 m |
Accounts Payable | 6.6 m | 11.4 m |
Total Debt | 22.1 m | |
Current Liabilities | 7.7 m | 11.4 m |
Additional Paid-in Capital | 117.7 m | 124.2 m |
Retained Earnings | (196 m) | (215.5 m) |
Debt to Assets Ratio | 0.4 x |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Depreciation and Amortization | 501 k | 265 k |
Accounts Receivable | (69 k) | 69 k |
Inventories | 5.5 m | |
Accounts Payable | 2.9 m | 4.8 m |
Cash From Operating Activities | (36.9 m) | (48.2 m) |
Purchases of PP&E | (104 k) | (87 k) |
Cash From Investing Activities | (79 k) | (83 k) |
Long-term Borrowings | (89 k) | |
Cash From Financing Activities | 123.6 m | 11.8 m |
Interest Paid | 75 k | 242 k |
| USD | Y, 2016 |
|---|---|
EV/EBIT | -0.3 x |
EV/CFO | -0.3 x |
Revenue/Employee | 11.5 k |
Debt/Assets | 0.4 x |
